Researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) have received a $1.77 million grant from the National Institute on Drug Abuse (NIDA) to explore whether a drug called clavulanic acid can help patients recover from cocaine use disorder. Clavulanic acid is part of an existing therapy known as Augmentin, which combines clavulanic acid with amoxicillin and is used for the treatment of bacterial infections. Mary Morrison, MD, MS, Vice Chair for Research, Psychiatry and Professor of Psychiatry and Behavioral Science at LKSOM, is a senior investigator on the new grant. Scott Rawls, PhD, Professor of Pharmacology at the Center for Substance Abuse Research at LKSOM, is a co-investigator. The news was covered by outlets including the Philadelphia Inquirer, PhillyVoice, Sigma Xi SmartBrief, Scienmag, and News-Medical.net.